 Heres a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks Biotech Stocks Hitting 52-week Highs June 4 Biohaven Pharmaceutical Holding Co Ltd NYSE: BHVN argenx SE - ADR NASDAQ: ARGX BioMarin Pharmaceutical Inc. NASDAQ: BMRN BioXcel Therapeutics Inc NASDAQ: BTAI Imara Inc NASDAQ: IMRA Inari Medical Inc NASDAQ: NARI Intellia Therapeutics Inc NASDAQ: NTLA ORIC Pharmaceuticals Inc NASDAQ: ORIC Passage Bio Inc NASDAQ: PASG Qiagen NV NYSE: QGEN Replimune Group Inc NASDAQ: REPL Zentalis Pharmaceuticals Inc NASDAQ: ZNTLDown In The Dumps Biotech Stocks Hitting 52-week Lows June 4 Evofem Biosciences Inc NASDAQ: EVFMpriced its 28.5 million common stock offering Iterum Therapeutics PLC NASDAQ: ITRMStocks In Focus Adamas Regulatory Application For Label Expansion For Parkinsons Drug Accepted For Review Adamas Pharmaceuticals Inc NASDAQ: ADMS said the FDA has accepted its sNDA for Gocovri as a treatment for OFF episodes in Parkinsons disease patients receiving levodopa-based therapy. The company said the anticipated PDUFA action date is Feb. 1, 2021.Gocovri has already been approved for the treatment of dyskinesia in patients with Parkinsons disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.The stock rallied 18.56 to 3.13 in after-hours trading.Oxford Immunotech Approached With 400M Bid Medical diagnostics company Oxford Immunotec Global PLC NASDAQ: OXFD is being approached with a 15 per share or a 400 million offer by a consortium of private equity investors led by KKR and Ampersand Capital Partners, Reuters reported.The company had apparently approached several health care peers in the past year but was unsuccessful in striking a deal.The stock climbed 15.74 to 15 in after-hours trading.Related Link: Attention Biotech Investors: Mark Your Calendar For June PDUFA DatesAbbVie Forges Partnerships With 3 Institutions For Developing COVID-19 Antibody Treatment AbbVie Inc NYSE: ABBV announced a collaboration with Harbour BioMed, Utrecht University and Erasmus Medical Center to develop a novel antibody therapeutics to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus.The collaboration plans to study the fully human, neutralizing antibody 47D11 discovered by institutions that targets the conserved domain of the spike protein of SARS-CoV-2.AbbVie will support preclinical activities, while also preparing for later stage preclinical and clinical development work. The company has received an exclusive option for licensing the candidate.Merck Gets FDA Approval For Triple-combo Antibiotic To Treat Hospital-Acquired Pneumonia Merck Co., Inc. NYSE: MRK announced FDA approval of its Recarbrio - a triplet combination of imipenem-cilastatin and relebactam - to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in patients 18 years of age and older.Novartis Announces Positive Results For Asthma Study Novartis AG NYSE: NVS announced publication of full results from the Phase 3b ARGON study in Respiratory Medicine, which showed once-daily treatment with single inhaler, high- and medium-dose Enerzair Breezhaler demonstrated non-inferiority to a free combination of twice-daily, high-dose salmeterol xinafoatefluticasone propionate, plus once-daily tiotropium, delivered in two different devices, in improving quality of life in people with uncontrolled asthma.Among secondary analyses, improvements in lung function, asthma control, health status, and reductions in moderate exacerbations were observed with high-dose once-daily INDGLYMF compared to high-dose SalFlu plus Tio, the company said.PDS Biotech To Evaluate Lead Asset In Mid-Stage Study In Cervical Cancer PDS Biotechnology Corp NASDAQ: PDSB announced a Phase 2 clinical trial to evaluate its lead immunotherapy product, PDS0101, in combination with standard of care chemoradiotherapy for treatment of locally advanced cervical cancer.PDS101, according to the company, is being developed for multiple cancers associated with HPV infection, including anal, cervical and head and neck cancers. Results of a Phase 1 trial released in Sept. 2019 showed the investigational asset demonstrated potent in vivo induction of active killer T-cells that target cancer cells containing the cancer-causing HPV proteins, as well as an excellent safety profile with no limiting toxicities.Offerings Menlo Therapeutics Inc NASDAQ: MNLO said it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offeringThe stock slipped 14.03 to 1.90 in after-hours trading.On The Radar IPOs Applied Molecular Transport, a clinical-stage biopharma, priced its upsized initial public offering, or IPO, of 11 million shares at 14 per share compared to the initially estimated range of 12-14. The shares will begin trading on the Nasdaq under the ticker symbol AMTI.Stockholm, Sweden-based specialty pharma company Calliditas Therapeutics priced its IPO of 9.231 million shares, consisting of a public offering of 8.317 million ADSs, with each ADSs representing two common shares, and a concurrent private placement of 924,000 common shares to certain qualified investors in Europe and certain other jurisdictions outside of the U.S. The company expects to raise gross proceeds of 90 million from the offering. The offering was upsized from the initial plan of an offering worth 75 million. The shares will commence trading on the Nasdaq under the ticker symbol CALT.See more from Benzinga The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Mercks Triple Combo Antibiotic Revisiting The Coronavirus Vaccine Race: Updates On The 10 Candidates In Clinics The Daily Biotech Pulse: Regulatory Delay For Novartis Multiple Sclerosis Drug, FSD Gets Nod For COVID-19 StudyC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 